Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company is headquartered in Nashville, Tennessee and currently employs 91 full-time employees. The company went IPO on 2009-08-11. The firm is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
How did CPIX's recent EPS compare to expectations?
The most recent EPS for Cumberland Pharmaceuticals Inc is $-0.01, expectations of $.
How did Cumberland Pharmaceuticals Inc CPIX's revenue perform in the last quarter?
Cumberland Pharmaceuticals Inc revenue for the last quarter is $-0.01
What is the revenue estimate for Cumberland Pharmaceuticals Inc?
According to of Wall street analyst, the revenue estimate of Cumberland Pharmaceuticals Inc range from $ to $
What's the earning quality score for Cumberland Pharmaceuticals Inc?
Cumberland Pharmaceuticals Inc has a earning quality score of B+/53.842934. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Cumberland Pharmaceuticals Inc report earnings?
Cumberland Pharmaceuticals Inc next earnings report is expected in 2026-06-01
What are Cumberland Pharmaceuticals Inc's expected earnings?
Cumberland Pharmaceuticals Inc expected earnings is $, according to wall-street analysts.
Did Cumberland Pharmaceuticals Inc beat earnings expectations?
Cumberland Pharmaceuticals Inc recent earnings of $13.68M expectations.